Financings
Opensesame closes qualifying transaction
RTO Completion Secures Capital but Implies Significant Valuation Reset for Existing Shareholders
Executive Summary
- Vector Science and Therapeutics Corp. (formerly Opensesame Acquisition Corp.) completed a qualifying transaction via a three-cornered merger on April 24, 2026.
- The company raised $2,310,500 in concurrent non-brokered financing at $0.10 per subscription receipt.
- Trading will resume under the new ticker "PAIN" on the TSX Venture Exchange starting April 28, 2026.
- Total outstanding shares post-transaction are 153,259,380, resulting in an implied market capitalization of approximately $15.3 million.
- Insiders subscribed for 700,000 subscription receipts ($70,000) indicating some confidence, though this is a small portion of the total raise.
- Warrants issued from financing have an exercise price of $0.25 and expire June 27, 2028.
Material Impact
- The closing of the RTO was expected following the definitive agreement signed on April 14, 2026; therefore, the news is not unexpected but confirms execution.
- The financing amount ($2.3M) met the lower end of the previously announced target range ($2M-$3M), which is a positive confirmation of capital raising capability.
- However, the implied post-transaction valuation (~$0.10/share based on $15.3M cap and 153M shares) represents a significant devaluation compared to the historical trading price of Opensesame (up to $10.52 in September 2025).
- This suggests existing shareholders face substantial dilution or value erosion upon transition to the new ticker PAIN, as the market cap resets based on the new entity's cash and equity structure rather than the SPAC's speculative trading price.
- The news is Routine - Positive because it validates the deal completion but does not introduce fundamentally new upside beyond what was priced into the RTO announcement.
OPEN · Price
Company Overview
- Entity: Vector Science and Therapeutics Corp. (formerly Opensesame Acquisition Corp.).
- Flagship Project: Described in CEO quotes as "biomechanical device development, drug delivery and commercialization." No specific product names or clinical trial phases are disclosed in the provided news releases.
- Leadership: Bill Jackson is listed as Chief Executive Officer with claimed expertise in biomechanical devices and commercialization.
- Status: Transitioned from a Capital Pool Company (SPAC) to an operating public company via Reverse Takeover on April 24, 2026.